Oxybutynin — $0 with Membership

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Overactive Bladder

• Mirabegron
• Solifenacin
• Tolterodine

Also listed for Overactive Bladder / Urge Incontinence

• Solifenacin 5/10 mg tabs
• Tolterodine 1/2 mg tabs

Other medications in Urology

• Phenazopyridine
• Phosphodiesterase 5 inhibitors
• Sildenafil
• Silodosin
• Tadalafil
• Tadalafil (BPH)
• Tamsulosin
• Terazosin

About Oxybutynin

Oxybutynin is a commonly prescribed medication designed to bring relief to those struggling with overactive bladder (OAB) symptoms. If you experience frequent urges, urgency, or incontinence, oxybutynin might be a solution. At TheDrugClub, we believe managing your health shouldn't break the bank, which is why we offer significant savings on essential medications like oxybutynin.

Oxybutynin is primarily used to treat symptoms of overactive bladder (OAB). This common condition can manifest as a sudden, strong urge to urinate (urgency), frequent urination (frequency), and involuntary leakage of urine (urge incontinence). These symptoms can significantly impact daily life, causing discomfort, embarrassment, and disruption to routines. Oxybutynin can help individuals regain control and improve their quality of life, allowing them to participate in activities without constant worry. It

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Oxybutynin is approved for (FDA label)

Oxybutynin chloride is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. ( 1 ) Oxybutynin chloride extended-release tablets are also indicated for the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida). ( 1 ) Oxybutynin chloride extended-release tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Oxybutynin chloride extended release tablets are also indicated for the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida).

Source: Read the full FDA label on DailyMed. Label effective date: September 13, 2024.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Oxybutynin (FDA label)

Extended-release tablets 5 mg, 10 mg and 15 mg (3) Oxybutynin chloride extended-release tablets, USP are available as 5 mg, 10 mg and 15 mg tablets for oral use: Oxybutynin chloride extended-release tablets USP, 5 mg are white to off-white, round, beveled-edged, biconvex, coated-tablets debossed on one side with "255" and plain on other side. Oxybutynin chloride extended-release tablets USP, 10 mg are white to off-white, round, beveled-edged, biconvex, coated-tablets debossed on one side with "256" and plain on other side. Oxybutynin chloride extended-release tablets USP, 15 mg are white to off-white, round, beveled-edged, biconvex, coated-tablets debossed on one side with "257" and plain on other side.

Source: FDA prescribing information (DailyMed). Set ID: ec4fd95f-16dc-4acf-b560-b67b7aaef08b. SPL document ID: 0119c939-6479-4c0e-894e-aa7de0572b81. Label effective date: September 13, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Oxybutynin (FDA label)

The most common (incidence ≥5%) adverse reactions were dry mouth, constipation, diarrhea, headache, somnolence and dizziness. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Zydus Pharmaceuticals USA Inc. at 1-877-993-8779 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The safety and efficacy of oxybutynin chloride extended-release tablets (5 to 30 mg/day) was evaluated in 774 adult subjects who participated in five double-blind, controlled clinical trials.

Source: FDA prescribing information (DailyMed). Set ID: ec4fd95f-16dc-4acf-b560-b67b7aaef08b. SPL document ID: 0119c939-6479-4c0e-894e-aa7de0572b81. Label effective date: September 13, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Oxybutynin (FDA label)

Urinary retention ( 4 ) Gastric Retention ( 4 ) Uncontrolled narrow angle glaucoma ( 4 ) Known hypersensitivity to oxybutynin chloride or any component of oxybutynin chloride extended-release tablets ( 4 ) Oxybutynin chloride extended release tablets are contraindicated in patients with urinary retention, gastric retention and other severe decreased gastrointestinal motility conditions, uncontrolled narrow-angle glaucoma. Oxybutynin chloride extended release tablets are also contraindicated in patients who have demonstrated hypersensitivity to the drug substance or other components of the product. There have been reports of hypersensitivity reactions, including anaphylaxis and angioedema.

Source: FDA prescribing information (DailyMed). Set ID: ec4fd95f-16dc-4acf-b560-b67b7aaef08b. SPL document ID: 0119c939-6479-4c0e-894e-aa7de0572b81. Label effective date: September 13, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Oxybutynin (FDA label)

Angioedema: Angioedema has been reported with oxybutynin. If symptoms of angioedema occur, discontinue oxybutynin chloride extended-release tablets immediately and initiate appropriate therapy. ( 5.1 ) Central Nervous System (CNS) effects: CNS effects have been reported with oxybutynin. If patient experiences anticholinergic CNS effects, consider dose adjustment or discontinuation of oxybutynin chloride extended-release tablets. ( 5.2 ) Use with caution due to aggravation of symptoms: ○ Pre-existing dementia in patients treated with cholinesterase inhibitors ( 5.2 ), ○ Parkinson's disease ( 5.2 ), ○ Myasthenia gravis ( 5.3 ), and ○ Decreased gastrointestinal motility in patients with autonomic neuropathy. ( 5.4 ) Urinary Retention: Use with caution in patients with clinically significant bladder outflow obstruction because of the risk of urinary retention ( 5.5 ) Gastrointestinal Adverse Reactions: Use with caution in patients with gastrointestinal obstructive disorders or decreased intestinal motility due to risk of gastric retention.

Source: FDA prescribing information (DailyMed). Set ID: ec4fd95f-16dc-4acf-b560-b67b7aaef08b. SPL document ID: 0119c939-6479-4c0e-894e-aa7de0572b81. Label effective date: September 13, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Oxybutynin (FDA label)

Co-administration with other anticholinergic drugs may increase the frequency and/or severity of anticholinergic-like effects. ( 7 ) Co-administration with strong cytochrome P450 (CYP) 3A4 inhibitors (e.g., ketoconazole) increases the systemic exposure of oxybutynin. ( 7 ) The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. This may be of concern for drugs with a narrow therapeutic index. Anticholinergic agents may also antagonize the effects of prokinetic agents, such as metoclopramide. Mean oxybutynin plasma concentrations were approximately 2 fold higher when oxybutynin chloride extended-release tablets were administered with ketoconazole, a potent CYP3A4 inhibitor.

Source: FDA prescribing information (DailyMed). Set ID: ec4fd95f-16dc-4acf-b560-b67b7aaef08b. SPL document ID: 0119c939-6479-4c0e-894e-aa7de0572b81. Label effective date: September 13, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.